Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Availability:

  • Sort by:
  • Browse by:
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 presentations: 1 to 50 of 65 from CROI 2022
WELCOME AND DAILY ROADMAP
Landon Myer
University of Cape Town, Cape Town, South Africa
from CROI 2022 on February 15, 2022 8:30 AM-9:30 AM
NEW INSIGHTS INTO HIV RNA BIOLOGY   (ABSTRACT 60)
Michael Summers
University of Maryland Baltimore County, Baltimore, MD, USA
from CROI 2022 on February 15, 2022 8:30 AM-9:30 AM
UNDERSTANDING THE EPIDEMIOLOGY OF COVID-19: A GLOBAL PERSPECTIVE   (ABSTRACT 61)
Muge Cevik
University of St Andrews, St Andrews, United Kingdom
from CROI 2022 on February 15, 2022 8:30 AM-9:30 AM
INTRODUCTION OF SPEAKERS PART I
Jonathan Mermin
Centers for Disease Control and Prevention, Atlanta, GA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
TRENDS IN HIV TESTING AND LINKAGE TO HIV TREATMENT IN 41 COUNTRIES: 2016-2021   (ABSTRACT 89)
Bakary Drammeh
Centers for Disease Control and Prevention, Atlanta, GA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
DETECTING RECENT HIV INFECTIONS IN OUTPATIENT DEPARTMENTS: A MULTI-COUNTRY ANALYSIS   (ABSTRACT 90)
Suzue Saito
International Center for AIDS Care and Treatment Programs at Columbia University, New York, NY, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
HIV AND VIREMIA PREVALENCE IN NONMIGRATING MEMBERS OF MIGRANT HOUSEHOLDS IN UGANDA   (ABSTRACT 91)
Ruth Young
Johns Hopkins University, Baltimore, MD, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
THE IMPACT OF FREE ANTIRETROVIRAL THERAPY FOR NONCITIZEN PREGNANT WOMEN IN BOTSWANA   (ABSTRACT 92)
Christina Fennell
Harvard University, Washington, DC, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
LIVE QUESTIONS AND ANSWERS PART I
Bakary Drammeh
Centers for Disease Control and Prevention, Atlanta, GA, USA
Jonathan Mermin
Centers for Disease Control and Prevention, Atlanta, GA, USA
Christina Fennell
Harvard University, Washington, DC, USA
Suzue Saito
International Center for AIDS Care and Treatment Programs at Columbia University, New York, NY, USA
Ruth Young
Johns Hopkins University, Baltimore, MD, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
DO INCENTIVE VOUCHERS IMPROVE HIV TREATMENT OUTCOMES AMONG KEY POPULATIONS IN INDIA?   (ABSTRACT 93)
Sunil S Solomon
Johns Hopkins University, Baltimore, MD, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
THE COOPERATIVE RE-ENGAGEMENT CONTROLLED TRIAL: DURABLE VIRAL SUPPRESSION ASSESSMENT   (ABSTRACT 94)
Jesse O'Shea
Centers for Disease Control and Prevention, Atlanta, GA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
UPDATED EFFICACY, SAFETY, AND CASE STUDIES IN HPTN 083: CAB-LA VS TDF/FTC FOR PREP   (ABSTRACT 96)
Raphael J Landovitz
University of California Los Angeles, Los Angeles, CA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
CAB-LA PREP: EARLY DETECTION OF HIV INFECTION MAY REDUCE INSTI RESISTANCE RISK   (ABSTRACT 95)
Susan Eshleman
Johns Hopkins University School of Medicine, Lutherville, MD, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
LIVE QUESTIONS AND ANSWERS PART II
Susan Eshleman
Johns Hopkins University School of Medicine, Lutherville, MD, USA
Landon Myer
University of Cape Town, Cape Town, South Africa
Raphael J Landovitz
University of California Los Angeles, Los Angeles, CA, USA
Jesse O'Shea
Centers for Disease Control and Prevention, Atlanta, GA, USA
Sunil S Solomon
Johns Hopkins University, Baltimore, MD, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
INTRODUCTION OF SPEAKERS PART I
Sharon L Hillier
University of Pittsburgh Medical Center, Pittsburgh, PA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
LONG-ACTING INJECTABLE FOR PREVENTION OF HIV AND UNPLANNED PREGNANCY   (ABSTRACT 80)
Isabella Young
University of North Carolina at Chapel Hill, Carborro, NC, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
PHASE I STUDY OF COMBINATION ANTI-HIV NEUTRALIZING ANTIBODIES IN HIV-NEGATIVE ADULTS   (ABSTRACT 81)
Magdalena E Sobieszczyk
Columbia University, New York, NY, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
PHASE I PK, SAFETY, AND ACCEPTABILITY STUDY OF A 90-DAY TENOFOVIR VAGINAL RING   (ABSTRACT 82)
Albert Liu
San Francisco Department of Public Health, San Francisco, CA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
ISLATRAVIR DISTRIBUTION IN MUCOSAL TISSUES, PBMC, & PLASMA AFTER MONTHLY ORAL DOSING   (ABSTRACT 83)
Craig Walter Hendrix
Johns Hopkins University, Ellicott City, MD, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
LIVE QUESTIONS AND ANSWERS PART I
Craig Walter Hendrix
Johns Hopkins University, Ellicott City, MD, USA
Sharon L Hillier
University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Albert Liu
San Francisco Department of Public Health, San Francisco, CA, USA
Magdalena E Sobieszczyk
Columbia University, New York, NY, USA
Isabella Young
University of North Carolina at Chapel Hill, Carborro, NC, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
THE BIDIRECTIONAL EFFECTS OF HORMONE THERAPY AND PREP IN TRANSGENDER INDIVIDUALS   (ABSTRACT 84)
Jill Blumenthal
University of California San Diego, San Diego, CA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
PHASE IIA TRIAL OF ISLATRAVIR QM FOR HIV PREP: WEEK 24 METABOLIC AND RENAL OUTCOMES   (ABSTRACT 85)
Pippa J Macdonald
Desmond Tutu HIV Centre, Cape Town, Western Cape, South Africa
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
COUNTERFACTUAL ESTIMATION OF CAB-LA EFFICACY AGAINST PLACEBO USING EXTERNAL TRIALS   (ABSTRACT 86)
Deborah Donnell
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
DIFFERENT HIV PROTECTION FOR TRADITIONAL AND MEDICAL CIRCUMCISION IN HPTN 071(POPART)   (ABSTRACT 87)
Kidist Belay Zewdie
University of Washington, Seattle, WA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
CHOICE AND ADHERENCE TO DAPIVIRINE RING OR ORAL PREP BY YOUNG AFRICAN WOMEN IN REACH   (ABSTRACT 88)
Kenneth Ngure
Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya, Kenya
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
LIVE QUESTIONS AND ANSWERS PART II
Jill Blumenthal
University of California San Diego, San Diego, CA, USA
Jean-Michel Molina
University of Paris, Paris, France
Deborah Donnell
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Pippa J Macdonald
Desmond Tutu HIV Centre, Cape Town, Western Cape, South Africa
Kenneth Ngure
Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya, Kenya
Kidist Belay Zewdie
University of Washington, Seattle, WA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
INTRODUCTION OF SPEAKERS PART I
Nicolas Chomont
Université de Montréal, Montreal, Quebec, Canada
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
THE IMPACT OF 3BNC117 AND ROMIDEPSIN TREATMENT AT ART INITIATION ON HIV-1 PERSISTENCE   (ABSTRACT 62)
Ole Søgaard
Aarhus University Hospital, Aarhus, Denmark
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
THERAPEUTIC EFFICACY OF COMBINED ACTIVE AND PASSIVE IMMUNIZATION IN SHIV+ MACAQUES   (ABSTRACT 63)
Victoria E K Walker-Sperling
Beth Israel Deaconess Medical Center, Boston, MA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
AZD5582 PLUS SIV MABS TO REDUCE TISSUE RESERVOIRS IN ART-SUPPRESSED MACAQUES   (ABSTRACT 64)
Amir Dashti
Emory University, Avondale Estates, GA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
HIV-1 REMISSION WITH CCR5∆32∆32 HAPLO-CORD TRANSPLANT IN A US WOMAN: IMPAACT P1107   (ABSTRACT 65)
Yvonne Bryson
David Geffen School of Medicine at University of California, Los Angeles, CA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
LIVE QUESTIONS AND ANSWERS PART I
Yvonne Bryson
David Geffen School of Medicine at University of California, Los Angeles, CA, USA
Nicolas Chomont
Université de Montréal, Montreal, Quebec, Canada
Amir Dashti
Emory University, Avondale Estates, GA, USA
Ole Søgaard
Aarhus University Hospital, Aarhus, Denmark
Victoria E K Walker-Sperling
Beth Israel Deaconess Medical Center, Boston, MA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
UNBIASED AND MULTIOMIC ASSESSMENT OF HIV-1–INFECTED CELLS AT SINGLE-CELL RESOLUTION   (ABSTRACT 66)
Vincent H Wu
University of Pennsylvania, Philadelphia, PA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
EXPANSION AND EXTENSIVE RECIRCULATION OF HIV-INFECTED CELLS IN MULTIPLE ORGANS   (ABSTRACT 67)
Caroline Dufour
Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
SELECTION OF INTACT HIV-1 PROVIRUSES IN DEEP LATENCY DURING LONG-TERM ART   (ABSTRACT 68)
Kyra W Seiger
Ragon Institute, Cambridge, MA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
SINGLE-CELL MULTIOMICS REVEALS HIV-1 PERSISTENCE IN EXPANDED CYTOTOXIC T-CELL CLONES   (ABSTRACT 69)
Ya-Chi Ho
Yale University, New Haven, CT, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
DELAYED VIRAL REBOUND FOLLOWING ANTIBODY ADMINISTRATION IN INFANT MACAQUES   (ABSTRACT 70)
Jenna S Powers
Emory University School of Medicine, Decatur, GA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
LIVE QUESTIONS AND ANSWERS PART II
Caroline Dufour
Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
Katharine J Bar
University of Pennsylvania, Philadelphia, PA, USA
Ya-Chi Ho
Yale University, New Haven, CT, USA
Jenna S Powers
Emory University School of Medicine, Decatur, GA, USA
Kyra W Seiger
Ragon Institute, Cambridge, MA, USA
Vincent H Wu
University of Pennsylvania, Philadelphia, PA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
SYMPTOM DURATION IN COVID-19 CONVALESCENT PATIENTS: REGIONAL & CLINICAL ASSOCIATIONS   (ABSTRACT 97)
Jorge A Gallardo-Cartagena
Universidad Nacional Mayor de San Marcos, Bellavista, CALLAO, Peru
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
POST-ACUTE SEQUELAE OF SARS-COV-2: CLINICAL CONDITION COMPARISON IN A MATCHED COHORT   (ABSTRACT 98)
Michael A Horberg
Kaiser Permanente Mid-Atlantic Permanente Research Institute, Rockville, MD, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
INFLAMMATION, EXERCISE CAPACITY, CHRONOTROPY, AND SYMPTOMS IN POST-ACUTE COVID-19   (ABSTRACT 99)
Matthew S. Durstenfeld
University of California, San Francisco, San Francisco, CA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
SALIVA, NASAL & TEAR PK OF EIDD-1931 IN PATIENTS WITH COVID-19 RECEIVING MOLNUPIRAVIR   (ABSTRACT 100)
Laura Dickinson
University of Liverpool, Liverpool, United Kingdom
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
LIVE QUESTIONS AND ANSWERS PART I
Laura Dickinson
University of Liverpool, Liverpool, United Kingdom
Douglas D Richman
University of California San Diego, La Jolla, CA, USA
Matthew S. Durstenfeld
University of California, San Francisco, San Francisco, CA, USA
Jorge A Gallardo-Cartagena
Universidad Nacional Mayor de San Marcos, Bellavista, CALLAO, Peru
Michael A Horberg
Kaiser Permanente Mid-Atlantic Permanente Research Institute, Rockville, MD, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
PHASE III TRIAL OF MOLNUPIRAVIR IN ADULTS WITH MILD SARS-COV-2 INFECTION IN INDIA   (ABSTRACT 101)
Nagalingeswaran Kumarasamy
Chennai Antiviral Research and Treatment Clinical Research Site, Chennai, India
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
INTRAMUSCULAR SOTROVIMAB IS NONINFERIOR TO INTRAVENOUS SOTROVIMAB FOR COVID-19   (ABSTRACT 102)
Anita Kohli
Arizona Clinical Trials, Chandler, AZ, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
EFFECT OF SEROSTATUS ON THE EFFICACY OF SOTROVIMAB IN PREVENTING COVID-19 PROGRESSION   (ABSTRACT 103)
Adrienne E Shapiro
University of Washington, Seattle, WA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
CASIRIVIMAB AND IMDEVIMAB COMBINATION PROVIDES LONG-TERM PROTECTION AGAINST COVID-19   (ABSTRACT 104)
Meagan P O'Brien
Regeneron Pharmaceuticals Incorporated, Tarrytown, NY, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
CAMOSTAT IS NOT EFFECTIVE FOR MILD-MODERATE COVID-19 IN A PHASE II TRIAL OF ACTIV-2   (ABSTRACT 105)
Nikolaus Jilg
Massachusetts General Hospital, Boston, MA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
LIVE QUESTIONS AND ANSWERS PART II
Leah A Gaffney
Vir Biotechnology, MELROSE, MA, USA
Huldrych F Günthard
University Hospital Zurich, Zurich, Switzerland
Nikolaus Jilg
Massachusetts General Hospital, Boston, MA, USA
Nagalingeswaran Kumarasamy
Chennai Antiviral Research and Treatment Clinical Research Site, Chennai, India
Meagan P O'Brien
Regeneron Pharmaceuticals Incorporated, Tarrytown, NY, USA
Adrienne E Shapiro
University of Washington, Seattle, WA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
INTRODUCTION OF SPEAKERS PART I
David L Thomas
The Johns Hopkins School of Medicine, Baltimore, MD, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 presentations: 1 to 50 of 65 from CROI 2022